Insulin aspart Sanofi

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

inzulin aspart

Available from:

Sanofi Winthrop Industrie

ATC code:

A10AB05

INN (International Name):

insulin aspart

Therapeutic group:

Lijekovi koji se koriste u dijabetesu

Therapeutic area:

Šećerna bolest

Therapeutic indications:

Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Product summary:

Revision: 4

Authorization status:

odobren

Authorization date:

2020-06-25

Patient Information leaflet

                                32
B. UPUTA O LIJEKU
33
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
INSULIN ASPART SANOFI 100 JEDINICA/ML OTOPINA ZA INJEKCIJU
U BOČICI
inzulin aspart
Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo
otkrivanje novih sigurnosnih
informacija. Prijavom svih sumnji na nuspojavu i Vi možete pomoći.
Za postupak prijavljivanja
nuspojava, pogledajte dio 4.
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku, medicinskoj sestri
ili ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika, medicinsku sestru ili
ljekarnika. To uključuje i svaku moguću nuspojavu koja nije navedena
u ovoj uputi. Pogledajte
dio 4._ _
ŠTO SE NALAZI U OVOJ UPUTI
1.
Što je Insulin aspart Sanofi i za što se koristi
2.
Što morate znati prije nego počnete primjenjivati Insulin aspart
Sanofi
3.
Kako primjenjivati Insulin aspart Sanofi
4.
Moguće nuspojave
5.
Kako čuvati Insulin aspart Sanofi
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE INSULIN ASPART SANOFI I ZA ŠTO SE KORISTI
Insulin aspart Sanofi moderan je inzulin (inzulinski analog) s
brzodjelujućim učinkom. Moderni
inzulinski pripravci poboljšane su verzije humanog inzulina.
Insulin aspart Sanofi koristi se za snižavanje visoke razine šećera
u krvi u odraslih, adolescenata i
djece u dobi od 1 i više godina koji imaju šećernu bolest
(dijabetes). Šećerna bolest vrsta je bolesti kod
koje tijelo ne stvara dovoljno inzulina za kontroliranje razine
šećera u krvi. Liječenje inzulinom aspart
pomaže spriječiti komplikacije šećerne bolesti.
Inzulin aspart počinje snižavati razinu šećera u krvi 10 - 20
minuta nakon što ga injicirate, maksimalan
učinak postiže se 1 - 3 sata nakon injiciranja, a učinak traj
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo
otkrivanje novih sigurnosnih
informacija. Od zdravstvenih radnika se traži da prijave svaku sumnju
na nuspojavu za ovaj lijek. Za
postupak prijavljivanja nuspojava vidjeti dio 4.8.
1.
NAZIV LIJEKA
Insulin aspart Sanofi 100 jedinica/ml otopina za injekciju u bočici
Insulin aspart Sanofi 100 jedinica/ml otopina za injekciju u ulošku
Insulin aspart Sanofi 100 jedinica/ml otopina za injekciju u
napunjenoj brizgalici
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedan ml otopine sadrži 100 jedinica inzulina aspart* (što odgovara
3,5 mg).
Insulin aspart Sanofi 100 jedinica/ml otopina za injekciju u bočici
Jedna bočica sadrži 10 ml, što odgovara 1000 jedinica inzulina
aspart.
Insulin aspart Sanofi 100 jedinica/ml otopina za injekciju u ulošku
Jedan uložak sadrži 3 ml, što odgovara 300 jedinica inzulina
aspart.
Insulin aspart Sanofi 100 jedinica/ml otopina za injekciju u
napunjenoj brizgalici
Jedna napunjena brizgalica sadrži 3 ml, što odgovara 300 jedinica
inzulina aspart.
Jedna napunjena brizgalica može isporučiti dozu od 1 do 80 jedinica
u koracima od 1 jedinice.
*proizveden tehnologijom rekombinantne DNK u bakteriji_ Escherichia
coli_._ _
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Otopina za injekciju (injekcija).
Bistra, bezbojna, vodena otopina.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Insulin aspart Sanofi indiciran je za liječenje šećerne bolesti u
odraslih, adolescenata i djece u dobi od
1 i više godina.
4.2
DOZIRANJE I NAČIN PRIMJENE
Doziranje
Jačina inzulinskih analoga, uključujući inzulin aspart, izražava
se u jedinicama, dok se jačina humanog
inzulina izražava u internacionalnim jedinicama.
Doziranje lijeka Insulin aspart Sanofi individualno je i određuje se
u skladu s potrebama bolesnika.
Obično se primjenjuje u kombinaciji sa srednjedugodjelujućim ili
dugodjelujućim inzulinom.
3
Osim toga, Insulin aspart Sanofi bočica može se koristiti z
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 07-07-2023
Public Assessment Report Public Assessment Report Bulgarian 07-07-2020
Patient Information leaflet Patient Information leaflet Spanish 07-07-2023
Public Assessment Report Public Assessment Report Spanish 07-07-2020
Patient Information leaflet Patient Information leaflet Czech 07-07-2023
Public Assessment Report Public Assessment Report Czech 07-07-2020
Patient Information leaflet Patient Information leaflet Danish 07-07-2023
Public Assessment Report Public Assessment Report Danish 07-07-2020
Patient Information leaflet Patient Information leaflet German 07-07-2023
Public Assessment Report Public Assessment Report German 07-07-2020
Patient Information leaflet Patient Information leaflet Estonian 07-07-2023
Public Assessment Report Public Assessment Report Estonian 07-07-2020
Patient Information leaflet Patient Information leaflet Greek 07-07-2023
Public Assessment Report Public Assessment Report Greek 07-07-2020
Patient Information leaflet Patient Information leaflet English 07-07-2023
Public Assessment Report Public Assessment Report English 07-07-2020
Patient Information leaflet Patient Information leaflet French 07-07-2023
Public Assessment Report Public Assessment Report French 07-07-2020
Patient Information leaflet Patient Information leaflet Italian 07-07-2023
Public Assessment Report Public Assessment Report Italian 07-07-2020
Patient Information leaflet Patient Information leaflet Latvian 07-07-2023
Public Assessment Report Public Assessment Report Latvian 07-07-2020
Patient Information leaflet Patient Information leaflet Lithuanian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-07-2023
Public Assessment Report Public Assessment Report Lithuanian 07-07-2020
Patient Information leaflet Patient Information leaflet Hungarian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 07-07-2023
Public Assessment Report Public Assessment Report Hungarian 07-07-2020
Patient Information leaflet Patient Information leaflet Maltese 07-07-2023
Public Assessment Report Public Assessment Report Maltese 07-07-2020
Patient Information leaflet Patient Information leaflet Dutch 07-07-2023
Public Assessment Report Public Assessment Report Dutch 07-07-2020
Patient Information leaflet Patient Information leaflet Polish 07-07-2023
Public Assessment Report Public Assessment Report Polish 07-07-2020
Patient Information leaflet Patient Information leaflet Portuguese 07-07-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 07-07-2023
Public Assessment Report Public Assessment Report Portuguese 07-07-2020
Patient Information leaflet Patient Information leaflet Romanian 07-07-2023
Public Assessment Report Public Assessment Report Romanian 07-07-2020
Patient Information leaflet Patient Information leaflet Slovak 07-07-2023
Public Assessment Report Public Assessment Report Slovak 07-07-2020
Patient Information leaflet Patient Information leaflet Slovenian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 07-07-2023
Public Assessment Report Public Assessment Report Slovenian 07-07-2020
Patient Information leaflet Patient Information leaflet Finnish 07-07-2023
Public Assessment Report Public Assessment Report Finnish 07-07-2020
Patient Information leaflet Patient Information leaflet Swedish 07-07-2023
Public Assessment Report Public Assessment Report Swedish 07-07-2020
Patient Information leaflet Patient Information leaflet Norwegian 07-07-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 07-07-2023
Patient Information leaflet Patient Information leaflet Icelandic 07-07-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 07-07-2023

Search alerts related to this product